Disease or Syndrome – Page 77

Peyronie’s disease, men’s health, Endo, “I Got Somebody” campaign, urology specialists, nonsurgical treatment options, disease awareness, stigma reduction.

Biotech IPOs Kick Off 2025: Ascentage Pharma Raises $126M, Aardvark Therapeutics Files for IPO

10 months ago talkbio0Tagged Ascentage, biotech, Drug Industry, IPOs, Malignant Neoplasms, Obesity, Order Tubulidentata (organism), Pharma

Biotech IPOs, Ascentage Pharma, Aardvark Therapeutics, Cancer Treatment, Obesity Treatment, Pharmaceutical Industry

Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges

10 months ago talkbio0Tagged Achondroplasia, BioMarin, BridgeBio, CNP gene, Disorder of skeletal system, Dwarfism, genetic bone disorders, infigratinib, RBM-007, TransCon, Voxzogo

Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.

RFK Jr.’s Financial Ties to Gardasil Litigation Spark Conflict-of-Interest Concerns

10 months ago talkbio0Tagged CHARGE Syndrome, Conflict (Psychology), Gardasil, Litigation, Merck, RFK Jr., Secretary Nomination, Vaccines

RFK Jr., Gardasil, Merck, Conflict of Interest, Vaccine Litigation, HHS Secretary Nomination

FDA Delays Decision on Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Until April 2025

10 months ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Decision, Drug Approval, Elamipretide, Stealth BioTherapeutics, United States Food and Drug Administration

Barth Syndrome, Elamipretide, FDA Decision, Stealth BioTherapeutics, Drug Approval Delay

FDA Issues Boxed Warning for Anaphylaxis Risk with Multiple Sclerosis Drugs Copaxone and Glatopa

10 months ago talkbio0Tagged anaphylaxis, boxed, Cautionary Warning, Copaxone, glatiramer, Glatopa, Multiple Sclerosis, sandoz, Teva, United States Food and Drug Administration

FDA, boxed warning, anaphylaxis, multiple sclerosis, Copaxone, Glatopa, glatiramer acetate, Teva, Sandoz

FDA Adds Boxed Warning to Teva’s Copaxone and Generic Glatopa Due to Anaphylaxis Risk

10 months ago talkbio0Tagged acetate, anaphylaxis, boxed, Cautionary Warning, Copaxone, glatiramer, Glatopa, Hypersensitivity, Multiple Sclerosis, Risk, United States Food and Drug Administration

FDA Boxed Warning, Anaphylaxis Risk, Copaxone, Glatopa, Glatiramer Acetate, Multiple Sclerosis (MS) Treatment, Allergic Reaction